Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sumitomo Chemical Company, Limited (4005.T)
Tokyo, JP
Sumitomo Chemical Company, Limited is a global enterprise active across diverse sectors, including petrochemicals and plastics, advanced energy and functional materials, specialized IT-related chemicals, health and agricultural sciences, pharmaceuticals, and various other industrial services. Within its Petrochemicals & Plastics division, the company manufactures synthetic resins such as polyethylene, polypropylene, and polymethyl methacrylate, alongside raw components for synthetic fibers and a broad array of industrial chemical products. The Energy & Functional Materials unit supplies alumina and aluminum goods for energy applications, polymer and rubber additives, synthetic rubber for diverse uses including tires, footwear, and construction, as well as high-performance engineering plastics and lithium-ion battery components crucial for electronics and advanced automotive technologies. Sumitomo Chemical's IT-Related Chemicals segment develops polarizing films, touch screen sensors, and color resists essential for liquid crystal and OLED displays. This segment also produces photoresists and ultra-pure chemicals vital for semiconductor fabrication, in addition to compound semiconductor materials used in communication device components such as antenna switches. In the Health & Crop Sciences sector, the firm provides agricultural chemicals for crop protection, fertilizers, animal feed additives, and domestic insecticides. This segment also supplies active pharmaceutical ingredients and their intermediates, alongside solutions for managing infectious diseases. The Pharmaceuticals segment focuses on delivering both prescription medications and diagnostic agents. Finally, the "Others" segment encompasses a range of services, including the provision of electrical power and steam, the design, construction, and oversight of chemical facilities, comprehensive transportation and warehousing solutions, and detailed physical property and environmental analysis. Sumitomo Chemical has partnered with Ginkgo Bioworks to advance the development of bio-based chemicals. Established in 1913, the company maintains its corporate headquarters in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.73% | +19.83% | +16.88% | +8.11% | +30.73% | +34.55% | +68.21% | +34.79% | +5.54% | +27.18% | +32.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 6 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-10.7% Q1'26: -11.3% (vs Q1'25)
-
EPS growth Chemicals: +11.7%+57.6% ★ Q1'26: -365.5% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+2.3% Q1'26: +14.2% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+4.4% Q1'26: -1.5% (vs Q1'25)
-
ROIC Chemicals: +3.4%+4.7% ★ Q1'26: -1.7% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+0.3% Q1'26: -0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×5.14× Q1'26: 13.46× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 8 Rev. Ana. 6 EPS Ana. |
Mar 2027 9 Rev. Ana. 9 EPS Ana. |
Mar 2028 8 Rev. Ana. 8 EPS Ana. |
Mar 2029 3 Rev. Ana. 3 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.38T
est: 2.33T (+2.2%)
|
2.10T
est: 2.17T (-3.3%)
|
1.94T
est: 1.94T (+0.1%)
|
2.19T
est: 2.22T (-1.3%)
|
2.32T
est: 2.35T (-1.4%)
|
2.23T
est: 2.25T (-0.9%)
|
2.29T
est: 2.28T (+0.5%)
|
2.77T
est: 2.75T (+0.6%)
|
2.90T
est: 2.96T (-2.2%)
|
2.45T
est: 2.50T (-2.0%)
|
2.61T
est: 2.59T (+0.6%)
|
2.31T
2.29T – 2.36T
-10.7% YoY
|
2.40T
2.28T – 2.63T
+3.5% YoY
|
2.45T
2.43T – 2.47T
+2.3% YoY
|
2.43T
2.43T – 2.43T
-0.8% YoY
|
2.48T
2.36T – 2.73T
+2.0% YoY
|
| EBITDA |
246.52B
est: 167.93B (+46.8%)
|
281.05B
est: 156.99B (+79.0%)
|
249.70B
est: 139.94B (+78.4%)
|
303.00B
est: 160.33B (+89.0%)
|
276.28B
est: 169.88B (+62.6%)
|
252.17B
est: 162.14B (+55.5%)
|
295.98B
est: 164.35B (+80.1%)
|
345.13B
est: 198.59B (+73.8%)
|
215.21B
est: 213.81B (+0.7%)
|
43.65B
est: 227.05B (-80.8%)
|
282.64B
est: 235.71B (+19.9%)
|
210.53B
208.39B – 214.39B
-10.7% YoY
|
217.91B
207.52B – 239.61B
+3.5% YoY
|
222.95B
221.36B – 224.55B
+2.3% YoY
|
221.14B
221.14B – 221.14B
-0.8% YoY
|
225.66B
214.90B – 248.13B
+2.0% YoY
|
| EBIT |
127.35B
est: 33.52B (+279.9%)
|
164.45B
est: 31.34B (+424.8%)
|
139.39B
est: 27.93B (+399.0%)
|
195.89B
est: 32.00B (+512.1%)
|
163.79B
est: 33.91B (+383.0%)
|
120.43B
est: 32.37B (+272.1%)
|
159.96B
est: 32.81B (+387.6%)
|
188.46B
est: 39.64B (+375.4%)
|
47.25B
est: 42.68B (+10.7%)
|
-113.87B
est: 81.45B (-239.8%)
|
144.09B
est: 84.56B (+70.4%)
|
75.52B
74.75B – 76.91B
-10.7% YoY
|
78.17B
74.44B – 85.96B
+3.5% YoY
|
79.98B
79.41B – 80.55B
+2.3% YoY
|
79.33B
79.33B – 79.33B
-0.8% YoY
|
80.95B
77.09B – 89.01B
+2.0% YoY
|
| Net Income |
52.19B
est: 50.21B (+4.0%)
|
81.45B
est: 84.34B (-3.4%)
|
76.54B
est: 78.70B (-2.7%)
|
133.77B
est: 141.45B (-5.4%)
|
117.99B
est: 120.21B (-1.8%)
|
30.93B
est: 31.56B (-2.0%)
|
46.04B
est: 32.21B (+43.0%)
|
162.13B
est: 149.27B (+8.6%)
|
6.99B
est: 1.45B (+383.0%)
|
-311.84B
est: -254.30B (-22.6%)
|
38.59B
est: 30.29B (+27.4%)
|
65.40B
56.21B – 86.83B
+115.9% YoY
|
77.15B
48.89B – 102.96B
+18.0% YoY
|
82.54B
48.92B – 133.59B
+7.0% YoY
|
87.07B
81.33B – 93.94B
+5.5% YoY
|
93.20B
87.42B – 105.26B
+7.0% YoY
|
| SGA |
361.43B
est: 496.63B (-27.2%)
|
366.00B
est: 464.30B (-21.2%)
|
321.31B
est: 413.88B (-22.4%)
|
373.33B
est: 474.16B (-21.3%)
|
397.10B
est: 502.42B (-21.0%)
|
390.37B
est: 479.53B (-18.6%)
|
402.42B
est: 486.06B (-17.2%)
|
460.11B
est: 587.31B (-21.7%)
|
523.69B
est: 632.34B (-17.2%)
|
380.58B
est: 413.52B (-8.0%)
|
389.98B
est: 429.29B (-9.2%)
|
383.43B
379.53B – 390.47B
-10.7% YoY
|
396.88B
377.95B – 436.40B
+3.5% YoY
|
406.06B
403.16B – 408.97B
+2.3% YoY
|
402.76B
402.76B – 402.76B
-0.8% YoY
|
410.99B
391.39B – 451.92B
+2.0% YoY
|
| EPS |
31.93
est: 30.68 (+4.1%)
|
49.84
est: 51.54 (-3.3%)
|
46.81
est: 48.09 (-2.7%)
|
81.81
est: 86.44 (-5.4%)
|
72.17
est: 73.45 (-1.7%)
|
18.91
est: 19.29 (-2.0%)
|
28.16
est: 19.68 (+43.1%)
|
99.16
est: 91.21 (+8.7%)
|
4.27
est: 0.87 (+390.3%)
|
-190.69
est: -155.49 (-22.6%)
|
23.59
est: 17.90 (+31.8%)
|
39.47
34.35 – 53.06
+120.4% YoY
|
48.56
29.87 – 62.91
+23.0% YoY
|
51.59
29.89 – 81.63
+6.2% YoY
|
53.17
49.70 – 57.40
+3.1% YoY
|
56.95
53.42 – 64.32
+7.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan Opportunities Fund OPPJ | 1.02% | 2.87M | 0.58% |
| 2 | iShares MSCI Japan Small-Cap ETF SCJ | 0.36% | 928.4K | 0.50% |
| 3 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.36% | 2.04M | 0.58% |
| 4 | Goldman Sachs Data Enhanced International Equity ETF GIEQ | 0.33% | 34.2K | 0.30% |
| 5 | Xtrackers FTSE Developed ex US Multifactor ETF DEEF | 0.32% | 173.9K | 0.24% |
| 6 | HSBC Japan Screened Equity UCITS ETF HSJD.L | 0.27% | 939.0K | 0.18% |
| 7 | Lazard International Dynamic Equity ETF IDEQ | 0.24% | 3.14M | 0.40% |
| 8 | JPMorgan Diversified Return International Equity ETF JPIN | 0.21% | 751.5K | 0.37% |
| 9 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD dis WSCR.L | 0.19% | 1.52M | 0.23% |
| 10 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD acc WSCSRI.SW | 0.19% | 1.52M | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Akira Nakanishi | Managing Executive Officer | — | — |
| Hirokazu Murata | Managing Executive Officer | — | — |
| Hiroshi Niinuma | Executive Vice President & Director | — | male |
| Juan Ferreira | Managing Executive Officer | — | male |
| Keigo Sasaki | Senior Managing Executive Officer of Corporate Comm, Corp Planning, Acc & Finance and Rep Director | — | — |
| Koichi Ogino | SMEO of Prod. Tech., Prod. Safety Infr. Cen., Eng, Resp. Care, Purchasing, Logi. Mgmt | — | — |
| Masaki Matsui | Executive VP & Head of ICT & Mobility Solutions Division | — | male |
| Masao Shimizu | Managing Executive Officer | — | — |
| Megumi Sakuramoto | Chief ESG Analyst | — | male |
| Nobuaki Mito | President, CEO, Head of Advanced Medical Solutions Sector & Representative Director | — | male |
| Satoshi Honda | Managing Executive Officer | — | — |
| Seiji Takeuchi | Sr Managing Ex Officer, Head of Essential & Green Materials Sec, Bus Dev for Circular Carbon Eco | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4005.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
